Clincosm LogoSign in Get a demo

The Effect of Cannabis on Dementia Related Agitation and Aggression

Sponsor
TO Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT03328676
Collaborator
(none)
64
Enrollment
1
Location
2
Arms
20.3
Actual Duration (Months)
3.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The most common syndrome in patients with severe dementia is agitated behavior, which is often characterized by a combination of violent behavior (physical or verbal), restlessness, and inappropriate loudness. The treatment options for this syndrome are limited and lead to severe side effects. In vivo experiments on animals and clinical studies on adults show that cannabinoids could have a beneficial effect on behavioral disorders in general, and in dementia-related disorders in particular.

Additionally, medical cannabis patients have reported that cannabis aids in pain relief, increased appetite, and a sense of calm and peace of mind. Elderly patients suffering from dementia that experience this syndrome could also benefit from other quality of life aspects of the cannabis treatment such as reduction in medication consumption, weight gain and improvement of sleep.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

In this randomized, double-blind placebo-controlled trial, 60 patients will be randomly assigned to receive either CBD-A (30:1) cannabis rich low THC oil (30% CBD and 1% THC) or a placebo oil. The primary efficacy endpoint was a decrease of four or more points on the Cohen-Mansfield Agitation Inventory (CMAI) score by week 16, as compared to baseline. Secondary endpoints included improvement of other neurobehavioral symptoms.

The following questionnaires will be administered by trained staff at every visit: The CMAI, a to measure the types and frequencies of agitated behaviors, and the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) to measure behavioral disturbances.

Study Design

Study Type:
Interventional
Actual Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A Phase II, Randomized, Double-blind, Placebo-controlled TrialA Phase II, Randomized, Double-blind, Placebo-controlled Trial
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
A Phase II, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Avidekel Oil for the Treatment of Subjects With Agitation Related to Dementia
Actual Study Start Date :
Dec 7, 2017
Actual Primary Completion Date :
Aug 18, 2019
Actual Study Completion Date :
Aug 18, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: "Avidekel " cannabis oil 20:1 CBD:THC

The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.

Drug: Cannabis
Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Other Names:
  • CBD-A

    		•
    Placebo Comparator: placebo oil

    Patients in the control group will receive placebo.

    Drug: Placebo oil
    Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
    Other Names:
  • olive oil and chlorophyll

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Change in score of Cohen-Mansfield Agitation Inventory (CMAI) [week 16]

      Proportion of subjects achieving a decrease of four or more points on the Cohen-Mansfield Agitation Inventory (CMAI), a 29-item scale that measures the types and frequencies of agitated behaviors, each rated on a 7-point scale of frequency, where higher scores indicate greater agitation severity.

    Secondary Outcome Measures

    1. Change in score of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) [week 16]

      Proportion of subjects with change in score of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH). The greater the NPI-NH score, the more severe and frequent the behavioral disturbances

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Male or female subjects > 60 years old.

    • Written informed consent from participants legally authorized representative.

    • Subjects who are residing either in an institutionalized setting (e.g. dementia unit, nursing home, assisted living facility, or other residential care facility) or in a non-institutionalized setting where the subject is not living alone and is receiving 24-hour supervision via home health care or a family member. Subjects must have been at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the trial.

    • Diagnosis of Dementia (NCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) Criteria for at least 6 months prior to screening.

    • Mini-Mental State Examination (MMSE) < 26.

    • Clinically relevant Behavioral and Psychological Symptoms of Dementia (BPSD) operationally defined as NPI-NH agitation/ aggression sub score of ≥3 at screening.

    • Documented history of clinically relevant BPSD.

    • Ability to participate in study evaluation and ingest oral medication.

    • Subjects will be on stable concomitant medications regimen for the treatment of BPSD for at least one month prior to the screening visit.

    • Subjects will be on stable concomitant medications regimen for the treatment of concurrent conditions for at least one month prior to the screening visit.

    Exclusion Criteria:

    • Patients receiving any of the following medications: Astemizole, Cisapride, Pimozide or Terfenadine.

    • The agitation/aggression is attributable to concomitant medications, environmental conditions or psychiatric condition.

    • Patients with severe heart disease.

    • Subjects suffering from Epilepsy.

    • Subjects suffering from anxiety disorder.

    • Subjects who had psychiatric condition in the past OR suffering from psychosis.

    • Schizophrenia OR family history of Schizophrenia OR any other mental disorder.

    • Subjects with any other condition, which in the judgment of the investigator would prevent the subject from completing the study.

    • Any condition that the Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient.

    • Patients suffering from alcohol and/or substance abuse

    • Surgery within 30 days prior to screening or scheduled surgery during the study period.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Laniado Hospital Netanya Israel

    Sponsors and Collaborators

    • TO Pharmaceuticals

    Investigators

    • Principal Investigator: Vered Hermush, Dr, Laniado Hospital Geriatric Department

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    TO Pharmaceuticals
    ClinicalTrials.gov Identifier:
    NCT03328676
    Other Study ID Numbers:
    • TO_D02_2016
    First Posted:
    Nov 1, 2017
    Last Update Posted:
    Mar 8, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Dementia
    Psychomotor Agitation
    Chlorophyllin

    Study Results

    No Results Posted as of Mar 8, 2022